FY26 · Ended Jun 30, 2026 · View SEC filing
A sliver of sales earns over a quarter of profit
The Other segment earns 10.4% on its sales against 1.2% in drug distribution, so mix shapes profit growth.
For investorsWhat Cardinal Health's profit depends on from here
For foundersBuilding higher-margin services on a thin-margin network
Gross margin grew faster than the 14.2% revenue rise, which the filing credits primarily to acquired MSO platforms.
Paying suppliers later than customers pay lets growth release cash, but the filing ties this year's swing to timing.
Operating earnings rose 14.9% but pretax earnings only 3.47%; a lower tax charge restored part of the gap.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Cardinal Health from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
